Research programme: PDGFR-alpha antagonists - Boston Biomedical

Drug Profile

Research programme: PDGFR-alpha antagonists - Boston Biomedical

Alternative Names: BBI 5006

Latest Information Update: 30 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston Biomedical
  • Class Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 30 Apr 2012 No development reported - Preclinical for Cancer in USA (PO)
  • 24 Apr 2012 Boston Biomedical has been acquired by Dainippon Sumitomo Pharma
  • 02 May 2008 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top